These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 32772956

  • 41. Efficacy of vortioxetine on the physical symptoms of major depressive disorder.
    Christensen MC, Florea I, Lindsten A, Baldwin DS.
    J Psychopharmacol; 2018 Oct; 32(10):1086-1097. PubMed ID: 30047820
    [Abstract] [Full Text] [Related]

  • 42. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Sampson E, Mills NT, Hori H, Schwarte K, Hohoff C, Schubert O, Clark SR, Fourrier C, Baune BT.
    J Clin Psychiatry; 2023 Oct 04; 84(6):. PubMed ID: 37796652
    [Abstract] [Full Text] [Related]

  • 43. A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment.
    Basurte-Villamor I, Vega P, Roncero C, Martínez-Raga J, Grau-López L, Aguilar L, Torrens M, Szerman N.
    Neuropsychiatr Dis Treat; 2022 Oct 04; 18():965-976. PubMed ID: 35547266
    [Abstract] [Full Text] [Related]

  • 44. Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross-sectional analysis of baseline data from PERFORM-J.
    Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan KHX, Hammer-Helmich L, Fernandez J.
    J Affect Disord; 2019 Nov 01; 258():172-178. PubMed ID: 31426015
    [Abstract] [Full Text] [Related]

  • 45. Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study.
    Mattingly GW, Ren H, Christensen MC, Katzman MA, Polosan M, Simonsen K, Hammer-Helmich L.
    Front Psychiatry; 2022 Nov 01; 13():824831. PubMed ID: 35356713
    [Abstract] [Full Text] [Related]

  • 46. Antidepressant effectiveness of deep Transcranial Magnetic Stimulation (dTMS) in patients with Major Depressive Disorder (MDD) with or without Alcohol Use Disorders (AUDs): a 6-month, open label, follow-up study.
    Rapinesi C, Curto M, Kotzalidis GD, Del Casale A, Serata D, Ferri VR, Di Pietro S, Scatena P, Bersani FS, Raccah RN, Digiacomantonio V, Ferracuti S, Bersani G, Zangen A, Angeletti G, Girardi P.
    J Affect Disord; 2015 Mar 15; 174():57-63. PubMed ID: 25484178
    [Abstract] [Full Text] [Related]

  • 47. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms.
    Xue L, Bocharova M, Young AH, Aarsland D.
    J Affect Disord; 2024 Sep 15; 361():74-81. PubMed ID: 38838790
    [Abstract] [Full Text] [Related]

  • 48. A 6-Month Open-Label Study of Vortioxetine among Cancer Patients with Major Depressive Disorder (MDD).
    Ng CG, Abousheishaa AA, Low SY, Zainal NZ, Thong KS, Awaluddin AB, Loo TH, Yacob SB, Nik Jaafar NR, Abdul Taib NIA, Mohamad Kamal NAB, Ismail F, Zamaniah Wi W.
    Asian Pac J Cancer Prev; 2023 Aug 01; 24(8):2583-2591. PubMed ID: 37642043
    [Abstract] [Full Text] [Related]

  • 49. Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.
    Papalexi E, Galanopoulos A, Kontis D, Markopoulou M, Balta G, Karavelas E, Panagiotidis P, Vlachos T, Ettrup A.
    BMC Psychiatry; 2022 Aug 12; 22(1):548. PubMed ID: 35962369
    [Abstract] [Full Text] [Related]

  • 50. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder.
    McIntyre RS, Loft H, Christensen MC.
    Neuropsychiatr Dis Treat; 2021 Aug 12; 17():575-585. PubMed ID: 33654400
    [Abstract] [Full Text] [Related]

  • 51. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
    Subramaniapillai M, Mansur RB, Zuckerman H, Park C, Lee Y, Iacobucci M, Cao B, Ho R, Lin K, Phan L, McIntyre RS.
    Compr Psychiatry; 2019 Oct 12; 94():152113. PubMed ID: 31404802
    [Abstract] [Full Text] [Related]

  • 52. Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey.
    Raveendran S, Singh D, Burke MC, McAuliffe-Fogarty AH, Parikh SV, McIntyre RS, Roy A, Martin M, Chrones L, Opler MGA, Blair C, McCue M.
    BMC Psychiatry; 2023 Jun 26; 23(1):464. PubMed ID: 37365543
    [Abstract] [Full Text] [Related]

  • 53. Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study.
    Kim H, Baik SY, Kim YW, Lee SH.
    Neuropsychopharmacol Rep; 2022 Mar 26; 42(1):21-31. PubMed ID: 34894110
    [Abstract] [Full Text] [Related]

  • 54. Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
    McIntyre RS, Florea I, Tonnoir B, Loft H, Lam RW, Christensen MC.
    J Clin Psychiatry; 2017 Jan 26; 78(1):115-121. PubMed ID: 27780334
    [Abstract] [Full Text] [Related]

  • 55. Effectiveness of Vortioxetine Treatment on Depression and Cognitive Functions in Patients with Alzheimer's Disease: A 12-Month, Retrospective, Observational Study.
    García-Alberca JM, De La Guia P, Gris E, Mendoza S, Lopez De La Rica M, Barbancho MÁ, Lara JP, Blanco-Reina E.
    J Pers Med; 2024 Aug 29; 14(9):. PubMed ID: 39338172
    [Abstract] [Full Text] [Related]

  • 56. Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.
    Wang G, Xiao L, Ren H, Simonsen K, Ma J, Xu X, Guo P, Wang Z, Bai L, Heldbo Reines E, Hammer-Helmich L.
    Neuropsychiatr Dis Treat; 2022 Aug 29; 18():1939-1950. PubMed ID: 36065389
    [Abstract] [Full Text] [Related]

  • 57. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
    Polosan M, Rabbani M, Christensen MC, Simonsen K, Ren H.
    Neuropsychiatr Dis Treat; 2022 Aug 29; 18():1963-1974. PubMed ID: 36068858
    [Abstract] [Full Text] [Related]

  • 58. Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea.
    Moon SW, Kim JW, Kim DH, Lee KY, Reines EH, Lee M, Park YJ.
    Front Psychiatry; 2023 Aug 29; 14():1075939. PubMed ID: 36937717
    [Abstract] [Full Text] [Related]

  • 59. Effectiveness and Safety of Vortioxetine for the Treatment of Major Depressive Disorder in the Real World: A Systematic Review and Meta-Analysis.
    Li Z, Liu S, Wu Q, Li J, Yang Q, Wang X, Peng P, Wang Q, Liu Y, Li M, Hao Y, Xu H, He L, Wang Y, Chen S, Liu T.
    Int J Neuropsychopharmacol; 2023 Jun 23; 26(6):373-384. PubMed ID: 37105713
    [Abstract] [Full Text] [Related]

  • 60. Comparison of vortioxetine and sertraline for treatment of major depressive disorder in elderly patients: A double-blind randomized trial.
    Borhannejad F, Shariati B, Naderi S, Shalbafan M, Mortezaei A, Sahebolzamani E, Saeb A, Hosein Mortazavi S, Kamalzadeh L, Aqamolaei A, Ali Noorbala A, Namazi-Shabestari A, Akhondzadeh S.
    J Clin Pharm Ther; 2020 Aug 23; 45(4):804-811. PubMed ID: 32420649
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.